Skip to main navigation
Logo

Live - Corprorate Menu

  • About Us
    • Our Leadership
    • Diversity, Equity, and Inclusion
    • Collaborations
    • Compliance and Ethics
    • Corporate Giving
  • Our Focus
    • Cerebral Adrenoleukodystrophy
    • Sickle Cell Disease
    • Transfusion Dependant Beta-Thalassemia
  • Our Science
    • Our Approach to Gene Therapy
    • Our Treatment Process
    • Our Pipeline
    • Clinical Trials
  • Patients & Advocacy
    • Patient Advocacy
    • Patient Resources
    • Access Policy

Live - Top Nav

  • investors & media
  • contact us
  • careers
  • stories

Investors & Media

Overview Corporate Governance Press Releases Events & Presentations Analyst Coverage Stock Information SEC Filings Investor FAQs

Toolkit

  • Annual Meeting
  • Information Request
  • Sign Up for Email Alerts
  • RSS Feeds

Media Contacts

  • Sarah Alspach

    Chief Communications Officer

    (857) 299-6198

    sarah.alspach@bluebirdbio.com

  • Jess Rowlands

    Senior Director, Product Communications

    (857) 299-6103

    jess.rowlands@bluebirdbio.com

Investor Contacts

  • Courtney O’Leary

    Investor Relations

    (978) 621-7347

    coleary@bluebirdbio.com

bluebird bio Sets Record Date and Distribution Date for Planned Business Separation

  • Read more about bluebird bio Sets Record Date and Distribution Date for Planned Business Separation

bluebird bio Provides Update on Upcoming Planned Business Separation

  • Read more about bluebird bio Provides Update on Upcoming Planned Business Separation

bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions

  • Read more about bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions

2seventy bio Announces Upcoming Investor Events

  • Read more about 2seventy bio Announces Upcoming Investor Events

bluebird bio Secures $75 Million in Private Placement Equity Financing

  • Read more about bluebird bio Secures $75 Million in Private Placement Equity Financing

bluebird bio at Morgan Stanley 19th Annual Healthcare Conference

  • Read more about bluebird bio at Morgan Stanley 19th Annual Healthcare Conference

bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events

  • Read more about bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events

bluebird bio Reports Second Quarter Financial Results and Provides Operational Update

  • Read more about bluebird bio Reports Second Quarter Financial Results and Provides Operational Update

2021 Wedbush PacGrow Healthcare Conference

  • Read more about 2021 Wedbush PacGrow Healthcare Conference

bluebird bio Announces Q2 Earnings Call and Upcoming Investor Events

  • Read more about bluebird bio Announces Q2 Earnings Call and Upcoming Investor Events

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Quick Links

  • Patients & Advocacy
  • Investors & Media
  • Careers
  • Contact Us

CONTACT INFO

info@bluebirdbio.com

clinicaltrials@bluebirdbio.com

investor@bluebirdbio.com

medinfo@bluebirdbio.com

Live - Terms & Privacy

  • Terms of Service
  • Privacy Policy
  • Cookie Notice
  • Sitemap
© 2022 bluebird bio, Inc. All Rights Reserved. Corp-US-00175 04/22

Live - Social Links